Lu-177 targeting drug for returning or growing meningioma
Part of Brain & nervous system, Cancer clinical trials.
This Phase 1/2 study tests a targeted radioactive medicine (Lu-177-satoreotide) for meningiomas that keep coming back or keep growing. It works only if tumor imaging shows the tumor has the right “target” signal, and it aims to see how well it can control the disease and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can sign informed consent
- Your meningioma has been confirmed to be returning or growing by MRI and/or specialist testing
- Your tumor must be visible/measurable on scans (at least 1 cm)
- Your scan must show strong somatostatin receptor “target” signal (68Ga-DOTATOC PET/CT)
- You must have no good standard treatment options left
- Your general health and blood counts must be strong enough for study treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (everolimus and 177Lu-DOTATATE) for people with grade 2 or 3 meningioma that has grown despite prior treatments. It aims to see if this combination can slow or stop tumor growth.
This trial uses a special PET scan to find active tumor areas and then delivers a stronger dose of radiation to those spots. It is for people with aggressive or returning meningiomas who have not had brain radiation before.
This trial tests a radioactive drug called 177Lu-DOTATATE for people with recurrent meningioma (a type of brain tumor) that has grown after surgery and radiation. The drug targets a protein on the tumor cells and delivers radiation directly to them.
This Phase 2 study tests Lutathera to treat meningioma that cannot be safely removed with surgery and is still growing after radiation. It uses a special scan to make sure the tumor has the right target, and aims to improve tumor control and safety.
This trial tests a type of radiation therapy called Lu-177 Dotatoc (PRRT) for people with neuroendocrine tumors or other cancers that have high levels of a specific protein (sst2). It may be an option when standard treatments stop working or aren't available.
This trial tests a radioactive drug that targets a protein on tumor blood vessels to treat glioblastoma that has come back after standard treatment. It may help shrink tumors or slow their growth.
Hear when a new Meningioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.